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Abstract 
In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been 
demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clini-
cal use of Octagam® 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam®, for 
conditions represented by five distinct indication groups. The results of this review indicate that Octagam® has been 
well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current prac-
tices, 85 % of Octagam’s utilization was classified as appropriate based on Canadian IVIg guidelines.
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Background
History of IVIg
The first reported success of antibody therapy was in 
1890, when von Behring and Kitasato described how 
serum extracted from an infected rabbit could protect 
a naïve rabbit from the effects of diphtheria toxin [1]. 
With the advent of large-scale fractionation, and access 
to blood banks through the American Red Cross, the 
first immunoglobulin products became available in the 
1940s [2]. These products became routinely used by 
both subcutaneous and intramuscular route to prevent 
and treat infections [2]. Intramuscular administration 
of immune serum globulin was later described as a suc-
cessful therapeutic approach to treat a patient who had 
a primary immune deficiency (PID) in 1952 [3], and 
quickly became standard practice for the treatment of 
patients with antibody deficiency syndromes [2]. With 
improvements in manufacturing and purification pro-
cesses, several European companies began producing 
serum immunoglobulin suitable for intravenous admin-
istration in the 1960s [2]. With fewer reported side effects 
and improved efficacy [4, 5], intravenous administration 
became the mainstay approach for serum immunoglobu-
lin treatment. Today, commercially available intravenous 
human normal immunoglobulin (IVIg) products are pre-
pared from pooled plasma from large groups of healthy 
blood donors [1], providing a diversity of antibodies. 
Since its use as a replacement therapy for PID patients, 
the clinical use of IVIg has expanded and has become an 
important treatment option in a wide spectrum of dis-
eases. IVIg is used routinely in autoimmune and acute 
inflammatory conditions due to IVIg’s immune-modula-
tory and anti-inflammatory properties.
Current Canadian landscape
In Canada, IVIg products are distributed by the Cana-
dian Blood Services with the exception of Québec, where 
Héma Québec assumes this role. The products are dis-
tributed to Canadian blood banks within hospitals, at 
which point they are dispensed to patients as physicians 
prescribe them. IVIg is currently used as replacement 
therapy in primary and secondary immunodeficiencies. 
IVIg is also used as an immunomodulatory therapy in 
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a number of autoimmune diseases. Among the 8 IVIg 
products available in Canada, there are six different 
approved indications (replacement and immunomodu-
latory), including primary and secondary immunodefi-
ciencies (PID/SID)—each with several different primary 
pathologies, chronic B-cell lymphocytic leukemia (CLL), 
immune thrombocytopenic purpura (ITP), chronic 
demyelinating polyneuropathy (CIDP) and multifo-
cal motor neuropathy (MMN) although it is used for a 
variety of other indications with a range of data to sup-
port its use. Although no single product in Canada is 
indicated for all of these conditions, Canadian hospitals 
stock a variety of IVIg products that tend to be used 
interchangeably. Canada is the highest per-capita con-
sumer of IVIg products worldwide, and the usage of IVIg 
in Canada has been steadily increasing over the last two 
decades [6]. To help ensure IVIg use is in keeping with 
an evidence-based approach to the practice of medicine, 
the National Advisory Committee on Blood and Blood 
Products (NAC) and Canadian Blood Services developed 
evidence-based practice guidelines on the use of IVIg for 
various conditions [7–12]. The objectives of these guide-
lines were to examine the evidence for the use of IVIg 
in specific conditions and provide recommendations to 
physicians on the optimal utilization of IVIg therapy in 
various therapeutic areas.
Differences between IVIg products
Various product characteristics contribute to the toler-
ability of the IVIg preparation including form (liquid 
versus lyophilized), type of stabilizer, product purity, 
osmolarity, concentration, IgG and IgA content, pH, 
osmolality, and sodium content [13, 14]. IVIg therapy 
is generally well tolerated [15–17], with most adverse 
events being mild, reversible infusion related events 
such as rigors, low-grade fever, headache, myalgia, back-
ache, flushing, and nausea [17, 18]. The incidence of mild 
adverse events is reported to be between 5 and 15 % per 
infusion [19]. Although some IVIg products may have a 
lower incidence of drug-related adverse reactions than 
others, differences in reporting, and lack of compara-
tive trial data makes this assertion difficult. Serious IVIg 
treatment-related adverse events are rarely reported, and 
are more common in patients with risk factors for poor 
prognosis [18, 19]. The safe and effective use of IVIg 
requires attention not only to product characteristics but 
also to administration issues and patient related risk-fac-
tors. It is critical that patients receiving IVIg therapy are 
carefully evaluated and monitored so that treatment can 
be optimized.
In terms of clinical efficacy, there are limited numbers 
of trials that directly compare two products head-to-
head. The small number of studies that compared two 
IVIg products were primarily licensing studies and not 
studies designed to compare product efficacy [20–23]. 
Dhainaut et al. compared in vitro and in vivo biological 
and biochemical properties of five liquid IVIg prepara-
tions. The authors concluded that the origin of plasma 
and the type of IVIg purification processes both con-
tribute to obtain a pharmaceutical product with distinct 
biochemical and physiological properties, although all 
IVIg preparations were found to be efficacious in various 
patients groups [24]. A Canadian consensus statement 
also considered different IVIg products to have compa-
rable clinical efficacy [11]. However, some patients may 
tolerate one product better than another [25, 26].
Efficacy, tolerability and safety of Octagam®
Octagam®, a liquid ready-to-use solvent deter-
gent treated IVIg, is manufactured by Octapharma 
Pharmazeutika (Vienna, Austria). First approved in 1995 
in Germany as a 5  % liquid human immunoglobulin 
preparation and in subsequent years the Octagam® 10 % 
formulation was available [27]. Octagam® has been in 
clinical use for over 20  years in 80 countries. Approved 
indications differ between IVIg formulations and coun-
tries [13]. Globally, Octagam® 5 % and 10 % are indicated 
for the treatment of primary and secondary immunode-
ficiencies, children with congenital AIDS and infection, 
Guillain–Barre Syndrome, Kawasaki Disease, allogenic 
bone marrow transplant, ITP and CIDP (5  % only) in 
the various global jurisdictions [13, 28]. Octagam® has 
been shown to be a safe and efficacious therapy, it is well 
tolerated and not associated with significant treatment-
related adverse reactions.
To date, one of the largest prospective studies on IVIg 
therapy evaluated the tolerability and safety of Octagam® 
[16]. Commencing in 1995, data were collected from 310 
study sites over a 10-year period. This study included 
6357 subjects with various PIDs, SIDs, and autoimmune 
diseases, who received 92,958 infusions. Adverse drug 
reactions were reported in 4.2 % of patients, which cor-
responded to 0.35  % of all infusions [16]. Most of the 
adverse events recorded were mild (55.9  %) or moder-
ate (34.3 %), and resolved quickly. The same study high-
lighted that there was no detectable relationship between 
the frequency of adverse drug reactions and elevated 
infusion rates or high dosages [16]. A recent prospective 
observational study in 117 PID patients compared the 
incidence of infusion-related adverse reactions of differ-
ent IVIg products [29]. Of a total of 1765 infusions, the 
overall incidence of infusion-related adverse reactions 
was only 2.15, 92  % of which were classified as mild or 
moderate in severity. This study found that there were 
significantly fewer infusion-related adverse reactions 
for patients treated with Octagam® (1.4  %) compared 
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with another IVIg product (5.6  %) [29]. Of note, the 
incidence of adverse reactions reported in this study 
were surprisingly low, and this observation was thought 
to be attributed to infusion adjustments made for most 
patients prior to study start, an enrollment criteria that 
the patients be experienced (most patients had previous 
exposure to multiple brands that may have desensitized 
them), and inclusion of adverse reactions that occurred 
only during infusion. An additional limitation to the 
study was the manual regulation of infusion rates, due to 
the absence of infusion pumps [29].
The safety and quality of Octagam® products is further 
ensured by the rigorous manufacturing process in which 
measures have been implemented to reduce the possi-
ble content of procoagulant factors. Testing of the final 
product also involves a thrombin generation assay that is 
designed to detect increased thromboembolic potential. 
Finally, to ensure viral safety is achieved—the manufac-
turing process involves two validated inactivation steps: 
a S/D method aimed at lipid enveloped virus inactivation, 
and a pH 4 treatment that reduces anti-complementary 
activation and aggregation of the IgG polymers. The S/D 
method is regarded by the World Hemophilia Federation 
as the “gold standard” in lipid enveloped virus inactiva-
tion [30]. This two-stage viral inactivation process has an 
excellent safety record [31], which is documented in the 
Octagam® pharmacoviligence data (Octapharma, data on 
file).
Canadian experience—Octagam® 10 %
As of April 2013, Octagam® 10  % became available to 
Canadian physicians and patients. Following approval in 
Germany in 1995, an open observations study was initi-
ated to evaluate the tolerably and long-term safety profile 
of Octagam® 5 % in routine clinical use in a wide variety 
of patients and diseases [16]. As the 10 % formulation is 
essentially similar to the less concentrated Octagam® 5 %, 
it was expected to be equally efficacious, safe and well 
tolerated. We present here the results of the first Cana-
dian retrospective file review that evaluated the routine 
clinical use of Octagam® across three Canadian institu-
tions: St. Paul’s Hospital in Vancouver British Columbia, 
St. Michael’s Hospital in Toronto Ontario, and St. Boni-
face Hospital in Winnipeg Manitoba.
Methods
Data was collected over a 1-year period in an anonymous 
manner from IVIG request forms which were collected 
by the Blood Banks at St. Paul’s Hospital in Vancou-
ver British Columbia, St. Michael’s Hospital in Toronto 
Ontario, and St. Boniface Hospital in Winnipeg Mani-
toba. The information included; the indications, the pre-
scribing physicians’ specialty, and the number of patients 
treated for a given indication. A separate analysis was 
performed to determine the appropriateness of IVIg use 
based on various published Canadian Consensus Guide-
lines for IVIg utilization [7–10].
Results
Over a 1-year period, a total of 135 patients were treated 
with Octagam® spanning 28 different indications (refer 
to Table  1). Similar to other IVIg products, Octagam® 
was prescribed to patients with diseases spanning several 
indication groups: immunology, hematology, neurology, 
rheumatology, and infectious disease. The proportion 
of patients that received Octagam® by indication is pre-
sented in Fig.  1. Octagam® was most often prescribed 
to patients with diseases included in the immunology 
indication (PID, SID, acute antibody mediated rejection, 
desensitization for kidney transplantation, and secondary 
immune deficiency due to malignancy). Notably, 36/58 
patients from this group were treated for PID. This was 
not surprising as two of the institutions involved have a 
dedicated immunology (immune deficiency) clinic. A 
large proportion of patients were also treated with Oct-
agam® for hematology indications, where 36/38 of these 
patients were diagnosed with ITP. A smaller proportion 
of patients treated were diagnosed with a neurological 
condition (23 patients, or 17 %)—however this included 
11 different disease categories. A small proportion of 
patients were also treated for rheumatology and infec-
tion disease indications. A total of 5 patients (3.7 %) were 
not categorized by indication group, and this included 
patients treated for a pneumonia query tuberculosis, 
treatment post coronary artery bypass graft surgery, sep-
tic shock, and a dental/gum problem.
Discussion
Globally, IVIg has been used in the treatment of approxi-
mately 100 different disease states and conditions. How-
ever, there is a paucity of compelling scientific evidence 
supporting many of these uses. Both the NAC and 
Ontario Regional Blood Coordinating Network (ORB-
CoN) monitor and evaluate IVIg utilization and related 
indications and these organizations provide useful guid-
ance to practitioners regarding the appropriate use of 
IVIg [7, 8, 11, 12, 32].
ORBCoN recently published an audit of the routine 
clinical use of IVIg products across Ontario in 2012 [32]. 
The audit included 2246 patients over a 3-month period 
with diseases spanning 120 different indications. The 
patients were treated with one of the five IVIg products 
that were licensed in Canada at the time, and the labeled 
versus unlabeled utilization was examined. Labeled indi-
cations referred to those that were approved for use by 
Health Canada for at least one of the IVIg products. 
Page 4 of 6Betschel et al. Allergy Asthma Clin Immunol  (2016) 12:32 
Using published clinical data, and Canadian IVIg guide-
lines [1, 7–10, 12, 18, 32] they summarized the off-label 
utilization (indications not approved by Health Canada) 
as either off-label and potentially indicated, or off-label 
and not indicated. Interestingly, their audit found that 
55 % of utilization was for labeled indications. Approxi-
mately 33 % of IVIg utilization in Ontario is for unlabeled 
but potentially clinically appropriate conditions or dis-
eases. This category includes disease states and condi-
tions for which there are supporting data but that have 
not been evaluated by Health Canada. Examples of 
unlabeled but potentially appropriate uses for IVIg in 
Ontario include myasthenia gravis, juvenile dermato-
myositis, pemphigus vulgaris and Guillain–Barre Syn-
drome. Lastly, 11  % of IVIg utilization was for off-label 
and not indicated. Examples of uses of IVIg in Ontario 
that are not considered fully supported by data but that 
are approved include kidney transplant, and hematopoi-
etic stem cell transplant. For a comprehensive review of 
IVIg utilization and approved uses please consult ORB-
CoN 2012 Final Audit Report on IVIg [32].
In other words, 88 % of the utilization was considered 
to be appropriate. Applying the same criteria set forth 
in the ORBCoN audit and the Canadian IVIg guide-
lines, each of the indications identified in this study were 
similarly classified. Utilization of Octagam® by three 
Canadian hospitals was found to be 65, 21, and 14  % 
Table 1 Patients treated with Octagam® 10 % across three Canadian institutions with corresponding indication group, 
and disease
Indication group Disease Number of patients Total number 
of patients
Immunology Primary immune deficiency 36 58
Secondary immune deficiency 10
Acute antibody mediated rejection 6
Desensitization for kidney transplantation 4
Secondary immune deficiency due to malignancy 2
Hematology Idiopathic thrombocytopenic purpura 36 38
Hemophagocytic lymphohistiocytosis 1
Pancytopenia/general weakness 1
Neurology Guillain-Barré syndrome 7 23
Myasthenia Gravis 3
Chronic inflammatory demyelinating polyneuropathy 3
Stiff person syndrome 2
Acute disseminated encephalomyelitis 2
Multifocal motor neuropathy 1
Acute sensimotor polyneuropathy 1




Rheumatology Dermatomyositis 6 7
Juvenile dermatomyositis 1
Infectious disease Group A streptococcus fasciitis 2 4
Staphylococcal toxic shock 1
Cellulitis 1
Miscellaneous Pneumonia query tuberculosis, post coronary artery bypass graft 
surgery, septic shock, dental/gum problem
5 5
Fig. 1 Percentage of patients treated with Octagam® 10 % by indica-
tion category
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for labeled (Health Canada has approved the indication 
for at least one IVIg product), off-label and potentially 
indicated, and off-label and not-indicated, respectively 
(Fig.  2). In other words, 86  % of the Octagam® utiliza-
tion was considered to be appropriate. These results sug-
gest that Octagam® is utilized in Canada like other IVIg 
products.
Conclusion
According to the 2012 ORBCoN audit, the clinical spe-
cialties that most often prescribed IVIg were neurol-
ogy, immunology and hematology, similar to the routine 
clinical use of Octagam® [32]. There have been several 
initiatives in Canada that have been aimed at ensuring 
that IVIg utilization remains appropriate and in align-
ment with an evidenced-based approach to the prac-
tice of medicine. This retrospective review reported 
the routine clinical use and Canadian experience with 
Octagam® in three hospitals over a 1-year period. Oct-
agam® was prescribed to patients across several disease 
indication groups including immunology, hematology, 
neurology, rheumatology and infection disease. When 
considering the Canadian IVIg guidelines, 116 of the 
135 cases where Octagam® was utilized were deemed 
to be appropriate [7–12, 32]. When compared to data 
from the 2012 ORBCoN Audit report of IVIg utiliza-
tion across Ontario, this review demonstrated that 
Octagam® utilization is similar to other IVIg products. 
Furthermore, these results suggest that Octagam® has 
been integrated into the system and is prescribed in 
Canada like other IVIg products. This is not surpris-
ing since generally IVIg products have been utilized in 
a way that would suggest they have similar clinical effi-
cacy and are interchangeable.
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